Edition:
United States

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

11.77EUR
8 Dec 2017
Change (% chg)

€0.03 (+0.26%)
Prev Close
€11.73
Open
€12.00
Day's High
€12.20
Day's Low
€11.72
Volume
175,635
Avg. Vol
104,626
52-wk High
€14.08
52-wk Low
€8.79

Chart for

About

Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The... (more)

Overall

Beta: --
Market Cap(Mil.): €600.84
Shares Outstanding(Mil.): 51.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 57.47 15.67
EPS (TTM): -- -- --
ROI: -- 13.36 34.62
ROE: -- 20.03 16.00

BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests

* BIOCARTIS AND AMGEN SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS

Dec 04 2017

BRIEF-Biocartis Raises 80 Million Dollars

* ANNOUNCED ON TUESDAY THAT IT RAISED EUR 80 MILLION IN GROSS PROCEEDS

Nov 29 2017

BRIEF-Bookrunner says Biocartis Group deal upsized to 80 mln euros From 60 mln euros base deal size‍​

* BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS DEAL UPSIZED TO 80 MILLION EUROS FROM 60 MILLION EUROS BASE DEAL SIZE‍​

Nov 28 2017

BRIEF-Biocartis Share Offering Of Up To About 8.9 mln Shares ‍​- bookrunner

* SAYS OFFERING DEAL SIZE ABOUT 60 MILLION EUROS‍​ Further company coverage:

Nov 28 2017

BRIEF-Biocartis Launches Equity Placement

* REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT

Nov 28 2017

BRIEF-Biocartis Group Launches Liquid Biopsy Tests with Merck

* ‍TESTS DEVELOPED UNDER PARTNERSHIP WITH MERCK KGAA, DARMSTADT, GERMANY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 27 2017

BRIEF-Biocartis Group sees ‍2017 guidance reiterated

* ‍CASH POSITION AT END OF Q3 2017 AMOUNTED TO APPROXIMATELY EUR 56 MILLION (UNAUDITED FIGURE)​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 16 2017

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* ‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​

Sep 13 2017

BRIEF-Biocartis H1 total operating income up at 6.8 million euros

* H1 TOTAL OPERATING INCOME EUR 7.0 MILLION VERSUS EUR 6.8 MILLION YEAR AGO

Sep 07 2017

BRIEF-Biocartis' Idylla respiratory panel receives clearance by FDA

* REG-BIOCARTIS GROUP NV: IDYLLA(TM) RESPIRATORY (IFV-RSV) PANEL RECEIVES 510(K) CLEARANCE BY US FDA Source text: http://bit.ly/2vGWUK1 Further company coverage: (Gdynia Newsroom)

Sep 05 2017

Earnings vs. Estimates